Company / Cash & Equivalents
Eton Pharmaceuticals, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$25.9M
FY2025
5-year range
$14.4M / $25.9M
FY2021-FY2025
Trend
+73.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 7 years, ranging from $12M in FY2019 to $26M in FY2025.
Based on SEC 10-K filings.
$26M in FY2025 with a 5-year CAGR of +4.0%.
Improved from $21M to $26M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.7%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 73.7% year-over-year.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.9M | +73.7% |
| FY2024 | $14.9M | -30.2% |
| FY2023 | $21.4M | +31.2% |
| FY2022 | $16.3M | +13.2% |
| FY2021 | $14.4M | -32.4% |
| FY2020 | $21.3M | +76.5% |
| FY2019 | $12.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026